Furthermore, it is worth nothing that RCN3 overexpression significantly dampened the anti-fibrotic effects of both drugs against TGFβ1-induced LF activation, suggesting that Rcn3 upregulation could restrain their therapeutic effects for IPF (Fig. 4F). The gene discussed is RCN3; the disease is idiopathic pulmonary fibrosis.